Keywords
SARCOMA
LI-FRAUMANI SYNDROME
ТР53 MUTATIONS
MULTIPLE PRIMARY NEOPLASM
How to Cite
Abstract
Sarcomas and brain tumors in children are a heterogeneous group of tumors, more than 7% of which may be a component of the Li-Fraumeni and Li-Fraumeni-like syndromes. The recognition these syndromes prior the adequate molecular testing is not always possible. This leads to late the diagnosis of tumor and not always adequate treatment. There are presented results of the molecular genetics diagnosis of the disease in four children with neoplasm arising in different organs and different periods in their life, between 2000 and 2015. Based on next-generation sequencing (NGS), test systems multiplex ligation-dependent probe amplification, Segner’s sequencing were detected a germline mutations of ТР53 gene in all children and some their relatives. Mutation in the gene ТР53, exon 7, с.С742Т (р.R248W) was reviled in one of these children, which inherited from his father affected multiple primary tumors. Besides, in this child discovered the second germinal missense mutation in the gene PPARG с.С254А (pP85Q), which inherited from the mother. Two missense mutations in the TP53 gene, exon 6 [c.619G> A (P.D207N) and c.644G> T (P.S215I)] identified in the second child, that inherited from the unaffected mother. The TP53 mutation exon 4, s.C328T (P.R110C) was revealed in the third child and the same mutations were detected in the child's mother and her 4 years old sister, who were healthy. Detected variants mutations indicated incomplete penetrance. The disease of the fourth child with intragenic deletion of exon 10 [c. (+ 11196- 1195 (1302 + 1_1303-1) del, P. (Ile332 ProfsTer14)] had the most aggressive course, with the development of 6 primary neoplasm. All identified genotypes had led to varying severity of disease symptoms in children. It is showed that the basis for the testing of mutations in the TP53 gene in children is early age of sarcomas, brain tumors and multiple primary neoplasms. Genetic TP53 testing should be offered their first-degree relatives. Because carriers of TP53 mutations have the risk of the other primary malignancy, they should be under active medical observing for life.
References
Birch J.M., Hartley A.L., Tricker K.J. et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families // Cancer Res. - 1994. - Vol. 54. - P. 1298-304.2. Bunyan D.J., Eccles D.M., Sillibourne J., Wilkins E. et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification // Br J Cancer. - 2004. - Vol. 91. - № 6. - P. 1155-1159. - DOI: 10.1038/sj.bjc.66021213. Evans D.G., Wu C.L., Birch J.M. BRCA2: A cause of Li-Fraumeni-like syndrome // J Med Genet. - 2008. -Vol.45. - P62-63.4. Foulkes W.D., Priest J.R., Duchaine T.F. DICER1: mutations, micrornas and mechanisms // Nat Rev Cancer. - 2014. - V. 10. - P. 662-72. - DOI: 10.1038/nrc38025. Goncalves A., Ewald I.P., Sapienza M. et al. Li-Fraumenilike syndrome associated with a large BRCA1 intragenic deletion // BMC Cancer. - 2012. - Vol. 12. - № 1. - P. 237-9. - DOI: 10.1186/1471-2407-12-2376. Hisada M., Garber J.E., Fung C.Y., Fraumeni J.F., Jr, Li F.P. Multiple primary cancers in families with Li- Fraumeni syndrome // J Nat Cancer Inst. - 1998. - Vol. 90. -P. 606-611.
Kansara M., Teng M.W., Smyth M.J., Thomas D.M. Translational biology of osteosarcoma // Nat Rev Cancer. - 2014. -Vol. 14. - № - 11. - P. 722-35. - DOI: 10.1038/nrc3838
Krepischi A.C., Pearson P.L., Rosenberg C. Germline copy number variations and cancer predisposition // Future Oncol. - 2012. - Vol.8. - № 4. - P441-450. - DOI: 10.2217/fon.12.34
Li F.P., Fraumeni J.F.Jr. Prospective study of a family cancers syndrome // JAMA. - 1982. - Vol. 247. - P. 2692-2694.
Li F.P., Fraumeni J.F. Jr, Mulvihill J.J. et al. A cancer family syndrome in twenty-four kindreds // Cancer Res. - 1988. - V. 48. - № 18. - P. 5358-5362.
Malkin D., Li F. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms // Science. - 1990. - Vol. 250. - P. 1233-1238.
Muoio D.M., MacLean P.S., Lang D.B., Li S., Houmard J.A. et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta // J Biol Chem. - 2002. - Vol. 277. - № 29. - P. 26089-97.
Nagy R., Sweet K., Eng C. Highly penetrant hereditary cancer syndromes // Oncogene. - 2004. - Vol.23. -№ 38. - Р. 6445-6470. - DOI: 10.1038/sj.onc.1207714
Narod S.A., Stiller C., Lenoir G.M. An estimate of the heritable fraction of childhood cancer // Br J Cancer. -1991. - Vol. 63. - P. 993-999.
Nichols K.E., Malkin D., Garber J.E., Fraumeni J.F., Jr, Li F.P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers // Cancer Epidemiol Biomarkers Prev. - 2001. - Vol. 10. - P. 83-7.
Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes // Nat Rev Mol Cell Biol. - 2008. - Vol. 9. - № 5. - Р. 402-12. - DOI: 10.1038/nrm2395
Sarraf P., Mueller E., Smith W. M., Wright H. M. et al. Loss-of-function mutations in PPAR-gamma associated with human colon cancer // Molec. Cell. - 1999. - № 3. - P.799-804.
Soussi and C. B'eroud. Assessing TP53 status in human tumours to evaluate clinical outcome // Nature Reviews Cancer. - 2001. - Vol. 1. - № 3. - Р. 233-240.
Tamori Y., Masugi J., Nishino N., Kasuga M. Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes. - 2002. - Vol. 51. - № 7. - P. 2045-55.
Uberti D., Schwartz D., Almog N. et al. Epithelial cells of different organs exhibit distinct patterns of p53-dependent and p53-independent apoptosis following DNA insult // Exp Cell Res. - 1999. - Vol.10. - № 252. - P. 123-33.
Valve R., Sivenius K., Miettinen R. et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women // J Clin Endocrinol Metab. - 1999. - Vol. 84. -№ 10. - P. 3708-12.
Zhelankin A.V., Sazonova M.A., Khasanova Z.B. et al. Analysis of mitochondrial haplogroups in persons with subclinical atherosclerosis based on high-throughput mtDNA sequencing // Patol Fiziol Eksp Ter. - 2015. -Vol. 59. - № 1. - P. 12-6.
Zhou X.P., Smith W.M., Gimm O., Mueller E. et al. Overrepresentation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population // J Med Genet. -2000. - Vol. 37. - № 6. - P. 410-4.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2017 Tatyana Kazubskaya, Vladimir Strelnikov, Natalya Pospekhova, Tatyana Kondrateva, Irina Sokolova, Yevgeniy Trofimov, V. Kozlova, Ye. Lukyanova, N. Shirokova, S. Mikhaylova